Search clinical trials for: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Total 88956 results

Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Fudan University

Unknown

Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Prostate Cancer

China
Peking University First Hospital

Not yet recruiting

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Prostate Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...
European Institute of Oncology; ASST Santi Paolo e Carlo

Recruiting

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment (APPROACH)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Italy
Sun Yat-sen University

Not yet recruiting

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Metastatic Prostate Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Metastatic Prostate Cancer | Intermitent Anti-androgen Therapy

China
Fondazione del Piemonte per l'Oncologia

Recruiting

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations (INSIDE)

Prostate Cancer

Italy
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Recruiting

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United States
Bayer

Active, not recruiting

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC)

Metastatic Hormone-sensitive Prostate Cancer

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Ignacio Puche Sanz
Chinese University of Hong Kong; UMC Utrecht; University of Padova; Medical University... and other collaborators

Not yet recruiting

BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Prostate Cancer Metastatic

Spain
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Metastatic Prostate Cancer | Therapy, Directly Observed

China
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer (DADOX)

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Japan
Pedro Barata, MD, MSc
ESSA Pharma Inc.

Not yet recruiting

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

United States
Peng Wang, MD PhD

Withdrawn

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Chemotherapy Effect | Metastatic Prostate Cancer | Hormone Sensitive Prostate Cancer

China
Xiao X. Wei, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Prostate Adenocarcinoma | Hormone Sensitive Prostate Cancer | Metastasis Prostate Adenocarcinoma

United States
Hongqian Guo
AstraZeneca; Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

Prostate Cancer | Metastatic Prostate Cancer | Prostate Carcinoma

China
Royal Marsden NHS Foundation Trust
Janssen, LP

Recruiting

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients (ADAPT-P)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United Kingdom
Jena University Hospital
Bayer

Recruiting

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Germany
Fudan University

Not yet recruiting

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment (CHAMPION)

Metastatic Prostate Cancer | Castration-Sensitive Prostate Cancer

China
Pfizer
Astellas Pharma Inc

Active, not recruiting

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Prostatic Neoplasms

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria

Malaria | Severe Malaria

Mali
Zhongnan Hospital

Recruiting

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Prostate Cancer | Castrate Resistant Prostate Cancer

China
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

Prostate Cancer

United States, France, Poland, Ukraine, United Kingdom, China, Spain, Argentina, Israel, Mexico, Romania, Turkey, Korea, Republic of, Japan, Sweden, Canada, Russian Federation, Brazil, Germany, Hungary, Czechia, Australia
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

Korea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
Pfizer
Astellas Pharma Inc

Active, not recruiting

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

Prostatic Neoplasms

United States
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, Austria, United Kingdom
Novartis Pharmaceuticals
Alliance Foundation Trials, LLC.; RTOG Foundation, Inc.

Active, not recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)

Prostatic Neoplasms

United States, China, Canada, Spain, United Kingdom, Belgium, Japan, Taiwan, Germany, Singapore, Austria, Netherlands, Korea, Republic of, France, Switzerland, Denmark, Sweden, Poland, Czechia
Astellas Pharma China, Inc.

Active, not recruiting

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (China ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
Qilu Hospital of Shandong University

Recruiting

Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study

Cohort Studies

China
Oscar Goodman, Jr.
Comprehensive Cancer Centers of Nevada

Withdrawn

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Prostate Cancer

United States
Medical University of Vienna
Lund University; Ziekenhuis Netwerk Antwerpen (ZNA); St. Antonius Hospital; Azienda... and other collaborators

Not yet recruiting

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study (OLIGOMET)

Prostate Cancer | Prostate Cancer Metastatic | Oligometastasis | Prostate Neoplasm | Oligometastatic Disease | Prostate Cancer Metastatic to Bone
Paul Viscuse

Not yet recruiting

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Metastatic Prostate Cancer | Castrate Sensitive Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Access to Genetic Testing in Underserved Patients With Cancer

Malignant Solid Neoplasm | Breast Carcinoma | Metastatic Prostate Carcinoma | Ovarian Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Pancreatic Exocrine Neoplasm | Stage IVB Prostate Cancer American Joint Committee on Cancer v8

United States
Swiss Group for Clinical Cancer Research

Not yet recruiting

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

Switzerland
Fusion Pharmaceuticals Inc.

Recruiting

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

Metastatic Castration-resistant Prostate Cancer

United States
858 Therapeutics, Inc.

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Advanced or Metastatic Solid Tumors | ER+ Breast Cancer | Castrate Resistant Prostate Cancer | BRCA Mutation

United States
Debiopharm International SA

Recruiting

A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer

Prostate Cancer

United States
Norroy Bioscience Co., LTD

Recruiting

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Metastatic Castration-resistant Prostate Cancer

China
AstraZeneca
Merck Sharp & Dohme LLC

Recruiting

Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) (PROceed)

Metastatic Castration-resistant Prostate Cancer

Germany
Institut de cancérologie Strasbourg Europe
Continuum Plus Santé; Plateforme nationale qualité de vie et cancer; WeShare

Recruiting

Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution (FEGALA)

Breast Neoplasms | Lung Neoplasms | Prostatic Neoplasms | Colorectal Neoplasms

France
Mayo Clinic

Not yet recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
Novartis Pharmaceuticals

Not yet recruiting

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Metastatic Neuroendocrine Prostate Cancer

Search clinical trials for: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations